Imperial Innovations leads £15m funding round for allergy vaccine developer | AltAssets Private Equity News

Subscribe today

Advanced
Search

Imperial Innovations leads £15m funding round for allergy vaccine developer

11 Dec 2009

Imperial Innovations, a technology commercialisation and investment company that backs innovations from Imperial College London, has led a £15.25m (€16.8m) funding round in Circassia, an allergy T-cell vaccine developer.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.